A Test in Focus

Ann Moyer, M.D., Ph.D., discusses an additional gene, NUDT15, which is important in the prediction of thiopurine-related toxicity This gene has been added to our TPMT genotyping assay available through Mayo Medical Laboratories.

By Mayo Medical Laboratories • October 25, 2017

Ann Moyer, M.D., Ph.D., discusses the importance of pharmacogenomics testing to limit adverse drug reactions and the new focused pharmacogenomics panel available through Mayo Medical Laboratories.

By Mayo Medical Laboratories • October 23, 2017

Devin Oglesbee, Ph.D., Director of the Biochemical and Molecular Genetics Laboratories at Mayo Clinic, provides an overview of the lysosomal storage disease panel, when it is appropriate to order this test, what actions the results allow you to take, and how this test improves upon previous approaches.

By Mayo Medical Laboratories • September 6, 2017

Gessi Bentz Pino, CGS, a Genetic Counselor in the Department of Laboratory Medicine and Pathology at Mayo Clinic, provides an overview of the lysosomal storage disorders screen, when it is appropriate to order this test, what actions the results allow you to take, and how this test improves upon previous approaches.

By Mayo Medical Laboratories • August 4, 2017

Dietrich Matern, M.D., Ph.D., discusses the importance of newborn screening, the conditions included within the Recommended Universal Screening Panel, and the new newborn screening panels available through Mayo Medical Laboratories.

By Mayo Medical Laboratories • July 10, 2017

Useful For Assessing the patient’s probability of having detectable prostate cancer when total prostate specific […]

By Mayo Medical Laboratories • May 9, 2017

Why is TPMT Testing Important? Detection of individuals with low thiopurine methyltransferase (TPMT) activity who […]

By Mayo Medical Laboratories • March 29, 2017

Mayo Clinic has one of the leading reference laboratories in the world that performs elemental analysis and metal testing for patients. Paul Jannetto, Ph.D., discusses Mayo’s testing menu and services.

By Mayo Medical Laboratories • March 3, 2017

Using targeted next-generation sequencing to identify lung tumors that may respond to targeted therapies by assessing somatic mutations simultaneously within EGFR, BRAF, KRAS, HRAS, NRAS, ALK, ERBB2 and MET and identifying rearrangements (fusions) involving ALK, ROS1, RET, and NTRK1.

By Brent Westra • December 14, 2016

Mayo Medical Laboratories now offers the following tests for Zika: MZIKP — Prenatal Zika and Dengue Virus Panel, IgM, Serum and MZIKA — Zika and Dengue Virus Panel, IgM, Serum.

By Brent Westra • September 1, 2016

Plasma ceramides are predictors of adverse cardiovascular events resulting from unstable atherosclerotic plaque. Three specific ceramides have been identified as highly linked to cardiovascular disease and insulin resistance: Cer16:0, Cer18:0, and Cer24:1. Jeff Meeusen, Ph.D., provides a video overview of this new test.

By Brent Westra • July 28, 2016

Chromosomal Microarray, Prenatal, Amniotic Fluid/Chorionic Villus Sampling is a high-resolution method for detecting copy number changes (gains or losses) across the entire genome in a single assay. Umut Aypar, Ph.D., provides a video overview of this test.

By Alyssa Frank • April 27, 2016

Cytochrome P450 2C19 (encoded by the gene CYP2C19) is a liver enzyme that participates in the activation of the anticoagulant clopidogrel (Plavix) and metabolism of other drugs, such as citalopram. As a result, Clopidrigrel may be less effective in altering platelet activity in those people, who may remain at risk for heart attack, stroke, and cardiovascular death.

By Alyssa Frank • March 31, 2016